MOR — Morphosys AG Share News
0.000.00%
Last trade - 00:00- €2.53bn
- €2.16bn
- €238.28m
Brief: Morphosys Repurchase Of Portion Of Outstanding Convertible Bonds Due 2025
Brief: Morphosys Invites Eligible Holders To Offer To Sell For Cash Their Convertible Bonds Due 2025
MorphoSys jumps pre-market on better-than-feared FY results
Brief: MorphoSys Q4 Consolidated Revenues Up At EUR 81.6 Mln
Brief: Morphosys Says Lucinda Crabtree To Join As Chief Financial Officer
Morphosys to slash early drug research programmes to preserve cash (updated)
Brief: Morphosys Stops Work And Operations On Pre-Clinical Research Programs And Reduces Workforce At Its Germany Headquarters
MorphoSys rises on 'encouraging' interim data from cancer drug trial
Brief: MorphoSys Expects Topline Data From Phase 3 Study Of Pelabresib In Myelofibrosis
Brief: MorphoSys: Preliminary 2022 Monjuvi U.S. Net Product Sales Of $89.4 Mln
Pharma, biotech to keep quality high in 2023 - JPM
Europe Research Roundup: Argenx, Rolls Royce, Thales
Europe Research Roundup: Hugo Boss AG, Londonmetric, Pandora
Brief: Chief Financial Officer Sung Lee To Leave Morphosys In March 2023
German pharma company MorphoSys's finance head to step down
Morphosys plunges after GS cuts to 'neutral'
Morphosys edges up after new results from ongoing cancer drug trial
Brief: Morphosys Presents New Longer-Term Phase 2 Results On Pelabresib
Brief: Eqs-News Morphosys Presents Updated Tafasitamab Results In Newly Diagnosed Dlbcl Patients From Final Firstmind Analysis